€0.20
-0.00 (-2.22%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where POXEL.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 2 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)NCT05146284Pharmacokinetic (PK) parametersRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Lack of funding to initiate the study | Drug: PXL770 | Adrenomyeloneuropathy | 0 | Sep 2024 | 2024-12-16 |
| Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)NCT05200104PharmacokineticOpen-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Funding unavailable | Drug: PXL065 | ALD (Adrenoleukodystrophy) | 0 | Sep 2024 | 2024-12-16 |
| Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)NCT04321343results2023-08-29Relative Change From Baseline to Week 36 in the Percentage of Liver Fat Content (LFC) (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF])Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PXL065, Placebo oral tablet | NASH - Nonalcoholic Steatohepatitis | 117 | 2022-06-08actual | 2023-08-29 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.NCT05441904CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: PXL770 | NASH - Nonalcoholic Steatohepatitis | 16 | 2021-03-29actual | 2022-07-01 |
| A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLDNCT03763877results2021-10-28Relative Change in the Percentage of Liver Fat Mass (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF]) From Baseline to Week 12/End of Treatment (EOT)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PXL770, Placebo Oral Capsule | Nonalcoholic Fatty Liver | 121 | 2020-08-03actual | 2021-10-28 |
| A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLDNCT03950882PK parameters of PXL770Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PXL770, Placebo | Nonalcoholic Fatty Liver | 17 | 2020-03-29actual | 2021-06-11 |
| Pharmacokinetics of Imeglimin in Hepatic Impaired SubjectsNCT03802786PK parameters of imegliminNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Imeglimin | Hepatic Impairment | 14 | 2019-07-03actual | 2020-08-11 |
| Pharmacokinetics and Metabolism of (14C)-Labelled PXL770NCT03886103Mass balance recoveryOpen-label · Treatment | Phase 1 | Completed | Drug: 14C labeled PXL770 | Healthy | 8 | 2019-03-15actual | 2019-03-22 |
| Bioequivalence of Imeglimin Tablet FormulationsNCT03646331Pk parameters of imegliminRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Imeglimin Reference product, Imeglimin | Bioequivalence | 16 | 2018-09-27actual | 2019-01-11 |
| Effect of Cimetidine on the PK of ImegliminNCT03618316PK parameters of imegliminOpen-label · Other | Phase 1 | Completed | Drug: Imeglimin, Cimetidine | Healthy | 16 | 2018-07-21actual | 2018-08-27 |
| Safety, Tolerability and PK of PXL770 in Healthy Male SubjectsNCT03395470Part A: PK parameters of PXL770 after repeated doses Part B: PK parameters of rosuvastatin before and after repeated doses of PXl770Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PXL770, Placebo, Rosuvastatin | Metabolic Disease | 60 | 2018-03-16actual | 2018-08-24 |
| Effect of Imeglimin on QT/QTc Intervals in Healthy SubjectsNCT02924337Change from baseline in QTcF (deltaQTcF)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, Imeglimin, Moxifloxacin | Qt Interval, Variation in | 55 | Dec 2016actual | 2017-02-10 |
| Safety, Tolerability and PK of Imeglimin in Japanese VolunteersNCT02373150PK parameters of imeglimin after single and repeated doses: - Cmax: peak plasma concentration after dosing, AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite time, - Tmax: time of peak plasma concentration of imegliminRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Imeglimin, Placebo | Type 2 Diabetes Mellitus | 48 | Oct 2015actual | 2017-02-10 |
| A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 DiabetesNCT01951235Change in HbA1cRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Imeglimin, Placebo | Type 2 Diabetes Mellitus | 315 | Jul 2014actual | 2015-08-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19